March 20, 2018

Primary Investigator: Dr. Lee Franco

Other Investigators: Anson Blanks

Chronic heart failure (CHF) is often a result of myocardial damage following ST-segment elevation myocardial infarction (STEMI). This damage is due in part to the recruitment of inflammatory monocytes by activation of the CCR2 receptor. Previous studies have suggested that Anakinra, an IL-1β receptor antagonist, may help to prevent the development of CHF, although the mechanism(s) responsible remain largely unknown. VCU-ART3 is a double-blind randomized clinical trial of Anakinra high dose vs Anakinra standard dose vs placebo in STEMI patients that aims to measure the effects of Anakinra on monocyte CCR2 expression during the first 14 days following STEMI.